David Linch

5PUBLICATIONS
6CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.

Elizabeth H Phillips, Catherine Burton, Amy A Kirkwood

|Dec 06, 2021
Therapy for isocitrate dehydrogenase 2 (IDH2)R172 -mutant acute myeloid leukaemia.

David C Linch, Robert K Hills, Alan K Burnett

|Nov 15, 2020
Developments over the last 60 years in diffuse large B-cell lymphomas.

David Linch

|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.

Mary Gleeson, Nicholas Counsell, David Cunningham

|Feb 01, 2020
The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.

David C Linch, Robert K Hills, Alan K Burnett

Pageof 1

Frequent Collaborators

2 joint publications

Robert K Hills

2 joint publications

Rosemary E Gale

1 joint publications

Nigel Russell

1 joint publications

Elizabeth H Phillips